Regeneron Pharmaceuticals Inc (REGN)
Price $955.47 · +0.45% today · $98.8B market cap.
biotech_pharma
Simulated history. Equities don't yet have ingested OHLCV, so the price chart and technical indicators below are illustrative (deterministic, labelled) — not real market history.
Price & Performance
$955.47 -10.8% over 1Y
Simulated history — illustrative, not real market data.
Today
+0.45%
1 week
+3.86%
1 month
+2.97%
1 year
+37.48%
Technical Analysis
RSI (14)
45.10
MACD
-8.14
MACD signal
-7.81
MACD hist
-0.33
SMA 20
962.50
SMA 50
979.83
EMA 20
965.43
ATR (14)
24.18
Support
933.12
Resistance
1006.42
Bollinger upper
984.10
Bollinger lower
940.90
- ▹ RSI 45 — neutral
- ▹ MACD below signal (bearish)
- ▹ Price below moving averages
Indicators describe past price action — they do not predict future direction.
Fundamental Analysis
P/E ratio
20.51
Return on equity
15.07%
EBITDA
n/a
EPS (TTM)
45.28
Net debt
n/a
Net margin
28.51%
Gross margin
86.79%
Current ratio
3.35
Debt / Equity
0.08
Dividend yield
0.39%
Operating margin
28.79%
Revenue growth (YoY)
18.59%
Risk Assessment
Ann. volatility
18.1%
Max drawdown
20.0%
Liquidity
Adequate market capitalization
Leverage
Debt/equity 0.1 (manageable)
Valuation
P/E 21×
Earnings
Earnings dates are not tracked in this release.
Concentration
Single-name equity — no diversification within the position.
Estimated annualized volatility 18% with a maximum drawdown of 20% over the available window.
Investment Thesis (generated summary)
Regeneron Pharmaceuticals Inc (REGN) screens constructively on the current data, with an opportunity score of 68/100. The score reflects the available fundamental, technical, valuation and sentiment inputs — it is a research screen, not a forecast or a recommendation to trade.
Bullish case
- Strong net margin (29%)
- Revenue growing 19% y/y
- Reasonable P/E (21×)
- Pays a dividend (0.4% yield)
Bearish case
- Underperforming peers
Potential catalysts
- 4 Dividend Stocks Retirees Can Buy Before They Go Ex-Dividend in the Week Ahead
- Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?
- Could You Have Held Glaukos Stock Through Its Falls?
Horizon: ~1–3 months for technical signals; 12+ months for fundamental quality.
Thesis invalidated if: Momentum reverses and price breaks below its 50-day average; Earnings or guidance disappoint relative to consensus; A sector-level drawdown outweighs stock-specific strength.
News Sentiment
Bullish 62.5%Neutral 12.5%Bearish 25%
Recent News
Yahoo2026-11-14
Yahoo2026-11-14
Benzinga2026-11-13
Benzinga2026-11-12
Yahoo2026-11-12
Disclaimer. AI-generated, informational and educational only. Not financial advice. Past performance does not indicate future results.